Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction
Michael E. Nassif(Saint Luke's Hospital), John M. Cox, Kenneth B. Margulies(Forthnet (Greece)), Silvio E. Inzucchi(Yale University), Brenda Murphy, Sheryl L. Windsor(Saint Luke's Hospital), Maria Rosa Costanzo, Sumant Lamba(First Coast Cardiovascular Institute), Bethany A. Austin(Saint Luke's Hospital), David E. Lanfear(Henry Ford Hospital), Alicia Warnock, JoAnn Lindenfeld(Vanderbilt University), R. Kannan Mutharasan(Northwestern University), W.H. Wilson Tang(Cleveland Clinic), Rita Jermyn(St. Francis Hospital), Shane LaRue(Washington University in St. Louis), Bertram Pitt(Bayer (Germany)), Mansoor Husain(University Health Network), Michael Pursley(The Heart House), Benjamin M. Scirica(Brigham and Women's Hospital), Ali O. Malik(Saint Luke's Hospital), Jonathan Newman, Mikhail Kosiborod(Copenhagen University Hospital), Nannette Wenger, Priyathama Vellanki(Emory University), Guillermo E. Umpierrez(Emory University), Stuart D. Katz(NYU Langone Health), Yevgeniy Khariton(Saint Luke's Hospital), Robert J. Mentz, Stephen S. Gottlieb, Paramdeep Baweja, Darren K. McGuire, Modele O. Ogunniyi, Mark H. Drazner(Southwestern Medical Center), Thanh T. Hoang, Larry A. Allen(Allen Institute), Michael M. Givertz(Brigham and Women's Hospital), Horng H. Chen, Charu Gupta, Michael Malone(Imaging the World), Justin Hartupee, Fengming Tang(Saint Luke's Hospital), Manuel Montero, Michael Fong(University of Southern California), Marcela Goldsmith, Robert Gordon(NorthShore University HealthSystem)
Cited by 427
Related Papers
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
|New England Journal of Medicine|2015|11.9k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k